Table of Contents
ZICOH® PATENTS ISSUED
MHA PARTNERSHIP
As Vivera grows, we have begun training the team to work closely with one of our most valued partners—Managed Health Care Associates, Inc. (MHA). Celebrating more than 30 years of service, MHA is the largest alternate site Group Purchasing Organization (GPO) in the country, and it encompasses Atlantic Health Partners, the nation’s largest vaccine buying group. Through Navigator Group Purchasing Inc., MHA has developed itself into a trusted leader in the long-term care space, offering full-service senior living products, services, and support nationwide.
This quarter, Vivera was proud to sponsor MHA’s 2021 Annual Business Summit, bringing together MHA members, customers, business partners, associates, and the communities we serve. We enjoyed networking with the MHA team and participating in this conference. With our virtual booth, we were able to showcase our current Advanced Diagnostics offerings and products from our Pharmaceutical and Medical Device divisions.
VACCINE & TESTING CLINICS
Vivera Cares has partnered with Central City Community Health Center in their COVID-19 and vaccination clinics throughout the Los Angeles and Orange County regions. Central City is a federally qualified non-profit health care center that offers health and human services to medically underserved and low-income populations. Together, we were able to provide complimentary COVID-19 testing and vaccines to over 800 people. The clinic was a massive success for our Vivera, earning recognition on ABC7, the ABC television network’s West Coast flagship station. Watch our video of the event here.
On April 15, Vivera hosted our first dedicated vaccine clinic in partnership with Capitol Health Services, the health services provider for the State of California capitol staff and lawmakers. Along with Sacramento County Public Health and EquiVax, Vivera will continue to host monthly vaccine and testing events in Sacramento and Los Angeles in order to support the growing demand for vaccination and testing.
NEUROSCIENCES DIVISION EXPANSION
Since appointing Dr. Gerald Maguire as Chief Neurosciences Advisor last quarter, the Vivera team has been hard at work on expanding the Neurosciences Division.
Focusing largely on psychiatric and fluency disorders, the Company has identified two new therapeutics to bring into our diverse pipeline. As we begin the first stages of R&D, Vivera will leverage the TABMELT® sublingual technology. This precision-dose delivery system will be especially important for treating patients with mild and severe psychiatric and neurological disorders.
Vivera is proud to welcome its first Neurosciences Ambassador, Ms. Farah Al Qaissieh. As the founder of Stutter UAE, the first stuttering support initiative in the United Arab Emirates, Ms. Al Qaissieh has and continues to take progressive action toward international empowerment and increased social awareness for people who stutter (PWS).
With the first quarter of 2021 also came a new opportunity for Vivera’s neurosciences division and its leadership team. Vivera is proud to extend its congratulations to Chief Neurosciences Advisor Dr. Maguire on his recent formal selection to lead the stuttering advocacy group, the World Stuttering Network, as Chair of Research & Development.
With synergies realized beyond its initial venture in neurosciences, Vivera has continued to develop its relationship with the University of California at Riverside. In doing so, Vivera has been working with the University to evaluate the potential to develop and license additional targeted, novel therapeutics. Vivera is also exploring additional opportunities with UCR to be seen in the quarters to come.
